Simple Summary Pancreatic ductal adenocarcinoma is a leading cause of cancer death
worldwide. Due to the frequently late diagnosis, early metastasis and high therapy …

Simple Summary The great majority, more than 90%, of patients with pancreatic ductal
adenocarcinoma (PDAC) die within less than five years after detection of the disease …

Objective Pancreatic cancer is associated with poor prognosis and dismal survival rates.
This study aims to investigate roles of lncRNA UCA1-loaded exosomes secreted by …

Background Profound resistance to chemotherapy remains a major challenge in achieving
better clinical outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). Recent …

The modest clinical benefits of neoadjuvant chemotherapy (NAT) in pancreatic ductal
adenocarcinoma (PDAC) are associated with a lack of robust data on treatment‐induced …

Simple Summary Pancreatic cancer has a poor prognosis, which is largely due to resistance
to treatment. Tumor heterogeneity is a known cause for treatment failure and has been …

Simple Summary In this work, a smart gemcitabine delivery system based on magnetic
nanoparticles (MNP) is proposed. Gemcitabine (GEM) is a chemotherapeutic agent usually …

Pancreatic ductal adenocarcinoma (PDAC) presents a formidable challenge with high
lethality and limited effective drug treatments. Its heightened metastatic potential further …

The aim of this study was to determine possible anticancer effect of tomentosin, a natural
sesquiterpene lactone, on pancreatic cancer cells. The cytotoxic effect of tomentosin was …

Pancreatic adenocarcinoma (PAAD) is an extremely lethal disease worldwide. Brain‐
derived neurotrophic factor (BDNF) is a critical member of the neurotrophin polypeptide …